Iovance provides updates on Amtagvi (lifileucel)

In its latest (Q2) earnings report, Iovance confirmed plans to reduce its workforce by 19% in a bid to save $100 million in yearly costs due to lower than expected sales for Amtagvi.

Iovance has said it believes Amtagvi has $1 billion-plus annual sales potential, thanks to its availability to treat several thousand melanoma patients per year in the US and a list price of $515,000, but it still has a long way to go to meet that threshold.